Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Cellebrite DI (CLBT) over the last 6 years, with Q4 2025 value amounting to $369.7 million.

  • Cellebrite DI's Total Current Liabilities rose 2509.46% to $369.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $369.7 million, marking a year-over-year increase of 2509.46%. This contributed to the annual value of $369.7 million for FY2025, which is 2509.46% up from last year.
  • Per Cellebrite DI's latest filing, its Total Current Liabilities stood at $369.7 million for Q4 2025, which was up 2509.46% from $316.9 million recorded in Q3 2025.
  • Cellebrite DI's 5-year Total Current Liabilities high stood at $403.7 million for Q3 2021, and its period low was $170.6 million during Q1 2022.
  • In the last 5 years, Cellebrite DI's Total Current Liabilities had a median value of $235.9 million in 2024 and averaged $252.5 million.
  • As far as peak fluctuations go, Cellebrite DI's Total Current Liabilities plummeted by 5299.17% in 2022, and later surged by 3066.29% in 2025.
  • Quarter analysis of 5 years shows Cellebrite DI's Total Current Liabilities stood at $186.6 million in 2021, then grew by 11.36% to $207.8 million in 2022, then increased by 22.16% to $253.8 million in 2023, then rose by 16.42% to $295.5 million in 2024, then rose by 25.09% to $369.7 million in 2025.
  • Its Total Current Liabilities was $369.7 million in Q4 2025, compared to $316.9 million in Q3 2025 and $310.0 million in Q2 2025.